Orum Therapeutics
Peter Tran has a diverse work experience spanning multiple industries. Peter began their career as an Inventory Analyst at Victory Trading Company, where they managed records and improved customer relations. Peter then worked as a Laboratory Technician at International Micro Photonix, conducting spectral data analysis and performing equipment maintenance. Peter then transitioned to a Quality Control Analyst role at Charm Sciences, Inc., where they ensured product quality and investigated performance issues. Peter further expanded their laboratory skills as a Laboratory Technician at Wentworth Institute of Technology, where they prepared solutions and educated students on laboratory techniques. Peter continued their laboratory work at Sanofi, maintaining glassware stock and overseeing safety procedures. Peter then worked as a Research Technician at Massachusetts General Hospital, specializing in peptide synthesis and purification. At Ra Pharmaceuticals, Peter served as a Research Associate, performing routine analytical laboratory functions and synthesizing compounds. Peter then moved on to UCB, where they held roles as a Research Associate and Laboratory Operations Manager, overseeing laboratory operations. Most recently, Peter held the position of Manager, Lab Operations at Faze Medicines. Currently, they are employed as a Laboratory Operations Manager at Orum Therapeutics.
Peter Tran attended Boston University from 2007 to 2011, where they obtained a Bachelor of Arts degree in Biochemistry and Molecular Biology.
This person is not in any offices
Orum Therapeutics
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification.